Statin-associated gynecomastia: evidence coming from the Italian spontaneous ADR reporting database and literature
- 542 Downloads
The aim of this study was to add to the body of evidence on statin-induced gynecomastia based on data retrieved from the Italian spontaneous adverse drug reaction (ADR) reporting database.
Spontaneous ADR reports collected in the Italian database up to 31 December 2010 were assessed on a case-by-case basis in a search for evidence of a possible causal association between statins and gynecomastia. Cases of gynecomastia or possible gynecomastia, according to the Medical Dictionary of Regulatory Activities (MedDRA) classification, associated with statin use were retrieved from the database. The findings were compared with the available literature in PubMed.
The database contained 90,448 ADR reports on 21 December 2010. At least one statin was listed as the suspected drug in 2,862 reports, of which 1,334 concerned a male patient. Among these reports, we identified eight cases with the preferred term “gynecomastia” with a statin as suspected drug: four reports of rosuvastatin and four of atorvastatin. One additional report of an unspecified “breast disorder” in a male patient attributed to fluvastatin was identified and included as a possible case. Four case-reports of statin-induced gynecomastia published between 2006 and 2010 were retrieved from PubMed.
Our findings suggest an association between gynecomastia and statins as a drug class, and the occurrence of this ADR would appear to be more likely with active substances that show an higher potency in inhibiting HMG-CoA reductase enzyme. To date, the safety information provided on the labels of different statin-containing medicines is not standardized. Harmonization of this information would be helpful for both healthcare practitioners and patients.
KeywordsStatins Gynecomastia Adverse drug reaction Spontaneous reporting database
The study was supported by funds from the Emilia Romagna Region and the University of Bologna.
The authors declare that they have no conflict of interest.
- 2.Braunstein GD (2010) Epidemiology and pathogenesis of gynecomastia. UpToDate 19.3. Available at: http://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-gynecomastia
- 11.Federal Drug Administration (FDA) (2011) Lescol® (fluvastatin sodium)—prescribing information. FDA, Washington D.C.Google Scholar
- 12.Compendio Farmaceutico Telematico–Farmadati Italia (2011) Lescol® (fluvastatin sodium)—Riassunto delle Caratteristiche del ProdottoGoogle Scholar
- 13.Compendio Farmaceutico Telematico–Farmadati Italia (2011) Torvast® (atorvastatin calcium)—Riassunto delle Caratteristiche del ProdottoGoogle Scholar
- 14.Federal Drug Administration (FDA) (2011) Lipitor® (atorvastatin calcium)—prescribing information. FDA, Washington D.C.Google Scholar
- 16.Mozzicato P MedDRA: an overview of the medical dictionary for regulatory activities. Pharmaceut Med 23:65–75Google Scholar
- 18.Gruppo di lavoro OsMed (2011) L’uso dei farmaci in Italia. Rapporto nazionale anno 2010. Available at: http://www.agenziafarmaco.gov.it/sites/default/files/rapporto_osmed_2010_0.pdf
- 19.Uppsala Monitoring Centre (2011) Vigibase online: the World Health Organization’s adverse drug reaction database. Available at: http://www.who-umc.org. Accessed 26 Oct 2011